51
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Accumulated common variants in the broader fragile X gene family modulate autistic phenotypes

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Fragile X syndrome ( FXS) is mostly caused by a CGG triplet expansion in the fragile X mental retardation 1 gene ( FMR1 ). Up to 60% of affected males fulfill criteria for autism spectrum disorder ( ASD), making FXS the most frequent monogenetic cause of syndromic ASD. It is unknown, however, whether normal variants (independent of mutations) in the fragile X gene family ( FMR1, FXR1, FXR2 ) and in FMR2 modulate autistic features. Here, we report an accumulation model of 8 SNPs in these genes, associated with autistic traits in a discovery sample of male patients with schizophrenia ( N = 692) and three independent replicate samples: patients with schizophrenia ( N = 626), patients with other psychiatric diagnoses ( N = 111) and a general population sample ( N = 2005). For first mechanistic insight, we contrasted micro RNA expression in peripheral blood mononuclear cells of selected extreme group subjects with high‐ versus low‐risk constellation regarding the accumulation model. Thereby, the brain‐expressed miR‐181 species emerged as potential “umbrella regulator”, with several seed matches across the fragile X gene family and FMR2 . To conclude, normal variation in these genes contributes to the continuum of autistic phenotypes.

          Related collections

          Most cited references54

          • Record: found
          • Abstract: found
          • Article: not found

          The positive and negative syndrome scale (PANSS) for schizophrenia.

          The variable results of positive-negative research with schizophrenics underscore the importance of well-characterized, standardized measurement techniques. We report on the development and initial standardization of the Positive and Negative Syndrome Scale (PANSS) for typological and dimensional assessment. Based on two established psychiatric rating systems, the 30-item PANSS was conceived as an operationalized, drug-sensitive instrument that provides balanced representation of positive and negative symptoms and gauges their relationship to one another and to global psychopathology. It thus constitutes four scales measuring positive and negative syndromes, their differential, and general severity of illness. Study of 101 schizophrenics found the four scales to be normally distributed and supported their reliability and stability. Positive and negative scores were inversely correlated once their common association with general psychopathology was extracted, suggesting that they represent mutually exclusive constructs. Review of five studies involving the PANSS provided evidence of its criterion-related validity with antecedent, genealogical, and concurrent measures, its predictive validity, its drug sensitivity, and its utility for both typological and dimensional assessment.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome.

            Fragile X syndrome is the most frequent form of inherited mental retardation and is associated with a fragile site at Xq27.3. We identified human YAC clones that span fragile X site-induced translocation breakpoints coincident with the fragile X site. A gene (FMR-1) was identified within a four cosmid contig of YAC DNA that expresses a 4.8 kb message in human brain. Within a 7.4 kb EcoRI genomic fragment, containing FMR-1 exonic sequences distal to a CpG island previously shown to be hypermethylated in fragile X patients, is a fragile X site-induced breakpoint cluster region that exhibits length variation in fragile X chromosomes. This fragment contains a lengthy CGG repeat that is 250 bp distal of the CpG island and maps within a FMR-1 exon. Localization of the brain-expressed FMR-1 gene to this EcoRI fragment suggests the involvement of this gene in the phenotypic expression of the fragile X syndrome.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Genetics of autism spectrum disorders.

              Characterized by a combination of abnormalities in language, social cognition and mental flexibility, autism is not a single disorder but a neurodevelopmental syndrome commonly referred to as autism spectrum disorder (ASD). Several dozen ASD susceptibility genes have been identified in the past decade, collectively accounting for 10-20% of ASD cases. These findings, although demonstrating that ASD is etiologically heterogeneous, provide important clues about its pathophysiology. Diverse genetic and genomic approaches provide evidence converging on disruption of key biological pathways, many of which are also implicated in other allied neurodevelopmental disorders. Knowing the genes involved in ASD provides us with a crucial tool to probe both the specificity of ASD and the shared neurobiological and cognitive features across what are considered clinically distinct disorders, with the goal of linking gene to brain circuits to cognitive function. Copyright © 2011 Elsevier Ltd. All rights reserved.
                Bookmark

                Author and article information

                Journal
                EMBO Mol Med
                EMBO Mol Med
                10.1002/(ISSN)1757-4684
                EMMM
                embomm
                EMBO Molecular Medicine
                John Wiley and Sons Inc. (Hoboken )
                1757-4676
                1757-4684
                26 November 2015
                December 2015
                : 7
                : 12 ( doiID: 10.1002/emmm.v7.12 )
                : 1565-1579
                Affiliations
                [ 1 ] Clinical NeuroscienceMax Planck Institute of Experimental Medicine GöttingenGermany
                [ 2 ]DFG Research Center for Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB) GöttingenGermany
                [ 3 ] Department of Psychiatry and PsychotherapyUniversity of Halle HalleGermany
                [ 4 ] Department of Psychiatry and PsychotherapyUniversity Medicine Greifswald GreifswaldGermany
                [ 5 ] Epigenetics in Neurodegenerative DiseasesGerman Center for Neurodegenerative Diseases (DZNE) GöttingenGermany
                [ 6 ] Molecular NeurobiologyMax Planck Institute of Experimental Medicine GöttingenGermany
                [ 7 ] Molecular NeuroplasticityGerman Center for Neurodegenerative Diseases (DZNE) MagdeburgGermany
                [ 8 ] Department of BiochemistryUniversity of Würzburg WürzburgGermany
                [ 9 ] Interfaculty Institute for Genetics and Functional GenomicsUniversity Medicine Greifswald GreifswaldGermany
                [ 10 ] Institute for Community MedicineUniversity Medicine Greifswald GreifswaldGermany
                [ 11 ] KU LeuvenCenter for Human Genetics and Leuven Institute for Neurodegenerative Diseases LeuvenBelgium
                [ 12 ] Department of Biomedicine and PreventionUniversity of Rome “Tor Vergata” RomeItaly
                [ 13 ] Department of Psychiatry & PsychotherapyUniversity of Göttingen GöttingenGermany
                Author notes
                [*] [* ]Corresponding author. Tel: +49 551 3899 628; Fax: +49 551 3899 670; E‐mail: ehrenreich@ 123456em.mpg.de
                [†]

                These authors contributed equally to this work

                Article
                EMMM201505696
                10.15252/emmm.201505696
                4693501
                26612855
                bdcde8e7-098d-4233-8de1-baed6ca8a9de
                © 2015 The Authors. Published under the terms of the CC BY 4.0 license

                This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 30 July 2015
                : 21 October 2015
                : 26 October 2015
                Page count
                Pages: 15
                Funding
                Funded by: Max Planck Society
                Funded by: Max Planck Förderstiftung
                Funded by: DFG
                Funded by: BMBF
                Funded by: EXTRABRAIN EU‐FP7
                Funded by: EU‐AIMS
                Funded by: Innovative Medicines Initiative Joint
                Award ID: 115300
                Funded by: European Union's Seventh Framework Programme
                Award ID: FP7/2007‐2013
                Funded by: EFPIA Companies
                Funded by: Autism Speaks
                Funded by: Federal Ministry of Education and Research
                Award ID: 01ZZ9603
                Award ID: 01ZZ0103
                Award ID: 01ZZ0403
                Funded by: Ministry of Cultural Affairs and the Social Ministry of the Federal State of Mecklenburg‐West Pomerania
                Funded by: Siemens Healthcare
                Funded by: Erlangen
                Categories
                Embo16
                Embo27
                Research Article
                Research Articles
                Custom metadata
                2.0
                emmm201505696
                December 2015
                Converter:WILEY_ML3GV2_TO_NLMPMC version:4.7.2 mode:remove_FC converted:22.12.2015

                Molecular medicine
                fmr1,fmr2,fxr1,fxr2,mir‐181,pgas
                Molecular medicine
                fmr1, fmr2, fxr1, fxr2, mir‐181, pgas

                Comments

                Comment on this article